Gilead is not buying Achillion

Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) entered a worldwide license and collaboration agreement with Janssen Pharmaceuticals to develop one of Achillion's hepatitis C virus treatments but the stock price fell $1.63 to close at $9.05 after rumors that Gilead Sciences Inc. (Nasdaq: GILD) was buying Achilion were quashed. Gilead stock slipped 39 cents to close at $110.17.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.